Stay in touch
Prime news from our network.
#read
7 in one go - MEDICAL FORGE LEIPZIG starts a new round
MEDICAL FORGE Leipzig, an accelerator for young innovative medical technology companies on the BioCity Campus Leipzig, facilitates entry into the German healthcare market and brings seven international start-ups to Saxony.
05/04/2023
After the successful launch in 2022 with 8 international start-ups, the MEDICAL FORGE Leipzig – Accelerator for Medical Devices and Therapies is entering its second round. Seven teams will be supported in the 12-month programme on their way into the German healthcare market and benefit from the cooperation with the local innovation ecosystem in the healthcare sector.
The structural change project – funded by the Federal Ministry of Economics and Climate Protection – aims to create long-term jobs in Leipzig and the Central German region and to further strengthen Leipzig as a business location, particularly in the life sciences sector.
The MEDICAL FORGE offers fully equipped biochemistry laboratories, a 3D printer and electronics workstations in BIO CITY LEIPZIG, as well as coaching for teams in the areas of regulatory affairs, market access and business development.
During the Welcome Week (3 April to 7 April 2023), the teams not only got to know each other, but also discovered lots of interesting facts about the city of Leipzig on a city tour. Tuesday was all about networking. In a „World Café“ format, the teams had the opportunity to meet MEDICAL FORGE partners in a similar way to speed dating. Among others, the University Hospital Leipzig, the Sankt Georg Hospital Leipzig, Luther Rechtsanwälte, PROMEGA, the Office for Economic Development of the City of Leipzig and the Saxony Economic Development Agency were present. At the subsequent networking party, the teams exchanged ideas with the partners and the BIO CITY community in a relaxed atmosphere. Individual meetings are planned for Wednesday, 5 April 2023 to initiate the first collaborations.
„The number of applicants has tripled compared to the first round. The Accelerator programme itself and the Leipzig location are being recognised internationally,says Simone Haubner, COO of MEDICAL FORGE.
Teams of the 2nd round: ZuriMed (Switzerland) introduces the FiberLocker system to revolutionise soft tissue repair in orthopaedics and sports medicine (plaster grafts). SDS Optic (Poland) has developed a microprobe for the real-time diagnosis of breast cancer. Breast cancer is the most common type of cancer in women and the second most common type of cancer overall. The team at MUVON Therapeutics (Switzerland) is pursuing the goal of developing the world's first commercially viable and clinically relevant regenerative cell-based therapy for the treatment of diseases caused by muscle wasting. The initial focus is on the treatment of stress urinary incontinence (SUI), which affects over 200 million people worldwide. NeuroTrigger (Israel) is aiming to enter the German market with a wearable eyelid pacemaker that enables people with complete or partial facial paralysis to blink. Microx Sp Zo. O. (USA/Poland) has developed a remote monitoring product consisting of a set of disposable cartridges and a cloud-connected device for measuring CBC (blood count) and protein levels (CRP, PCT and IL-6) to enable physicians to categorise immunocompromised patients or patients undergoing chemotherapy into mild, moderate and severe cases. Glycanostics s.r.o. (Slovakia) has developed a highly precise and unique cancer diagnostic test based on the analysis of glycans in blood serum, which enables early diagnosis. This patented technology covers the possible diagnosis of eleven types of cancer. &about the MEDICAL FORGE MEDICAL FORGE Leipzig by biosaxony supports start-ups and innovative SMEs in bringing their medical products to the German healthcare market more quickly. The 12-month accelerator programme focuses on industry-specific topics such as approval, marketing, reimbursement and clinical evidence. Through individual coaching and mentoring as well as a market-specific training programme, selected start-ups are supported in further developing their software solutions and devices into finished medical products and implementing them in the clinical environment. Together with partners from industry, health insurance companies and clinics, the founders will continue to forge their products and services in order to bring them to market maturity.
The programme is funded by the Federal Ministry of Economics and Climate Protection on the basis of a resolution passed by the German Bundestag. &about biosaxony biosaxony is the national association for biotechnology, medical technology and the healthcare industry. Its members include companies, scientific institutions as well as stakeholders and suppliers in the industry. The network is complemented by representatives from the user side, such as clinics and health insurance companies. The network pools the strengths of all member companies and represents their interests in politics and the public sphere. The tasks of the cluster include the initiation of projects between industry and science, the provision of services and expertise as well as the presentation of regional competences in order to support the value-adding expansion of these cross-sectional technologies and to strengthen the economic region of Saxony. In addition, the promotion of young innovative companies is one of the network's main concerns.
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.